论文部分内容阅读
自1901年Pierre Curiee首先提出近距离治疗术语,放射性粒子组织间近距离治疗肿瘤已有100多年的历史。放射性粒子植入治疗包括短暂性植入治疗和永久性植入治疗。短暂性植入治疗常用放射性核素,包括60Co、192Ir和137Cs等,其释放的射线能量大,组织穿透力强,不易防护。永久性植入治疗常用的放射性素包括125I、103Pd、169Yb和198Au等,其释放的射线能量相对较低,组织穿透力相对弱,临床上相对易于防护。对于支气管肺癌的粒子治疗,125I和103Pd粒子临床上应用最常见的两种核素粒子。现就其临床应用现状及热点问题综述如下。
Pierre Curiee first proposed the brachytherapy term since 1901, and the brachytherapy of radioactive particle tissue has been in the history of more than 100 years. Radioactive seed implantation includes transient implant and permanent implant. Transient implantation of radionuclides commonly used in the treatment, including 60Co, 192Ir and 137Cs, the release of radiation energy, strong tissue penetration, easy to protect. The commonly used radiotrins for permanent implantation include 125I, 103Pd, 169Yb and 198Au, which release relatively low energy of radiation, relatively weak tissue penetration and relatively easy protection in clinical practice. For particle therapy of bronchogenic carcinoma, the 125I and 103Pd particles are clinically applied with the two most common nuclear particles. Now on the clinical application of the status and hot issues are summarized below.